Physician

Wei Wang, MD, PHD

According to 2025 Medicare claims, Wei Wang, MD, PHD (NPI: 1861482853) practices medical oncology in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Francisco, CA. This provider's primary affiliated billing organization is SAN FRANCISCO ONCOLOGY ASSOCIATES MEDICAL GROUP INC (NPI: 1457385379; TIN: 943255519) and primary practice location at 94115-2378. Wang is affiliated with the APA ACO Inc. (ACO ID: D0215), participating under the REACH model.

Wang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 136 traditional Medicare patients, billed 47,372 HCPCS/CPT codes, and received $898,624 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 870 prescription claims across 166 beneficiaries totaling $3,392,572 in drug costs, led by Tagrisso (Osimertinib Mesylate). 2023 DME data shows 26 claims. Open Payments data shows 53 records totaling $1,432. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $819,502 to $3,392,572. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	180	39,804	$799,566
2016	188	52,361	$733,040
2017	203	37,673	$717,108
2018	210	50,569	$873,620
2019	224	51,085	$1,068,230
2020	199	56,029	$829,572
2021	195	36,276	$599,064
2022	185	55,474	$923,913
2023	165	39,543	$795,286
2024	136	47,372	$898,624

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	86	540	$819,502
2016	95	588	$831,427
2017	101	561	$658,454
2018	92	490	$766,992
2019	111	653	$1,528,628
2020	134	871	$2,911,061
2021	126	724	$1,936,313
2022	119	663	$2,216,253
2023	135	713	$3,187,857
2024	166	870	$3,392,572

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	44	$23,860
2017	N/R	27	$6,974
2018	N/R	45	$6,266
2019	N/R	N/R	N/R
2020	N/R	55	$5,444
2021	N/R	27	$2,342
2022	N/R	44	$2,099
2023	N/R	26	$2,831
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	77	175	$106
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	86	154	$72
96372	Injection of drug or substance under skin or into muscle	22	82	$14
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	39	200	$8
36415	Insertion of needle into vein for collection of blood sample	42	181	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	97	2,910	$1,497,724
Trazimera	Trastuzumab-Qyyp	61	1,442	$219,963
Jakafi	Ruxolitinib Phosphate	13	390	$216,986
Kisqali	Ribociclib Succinate	12	336	$187,691
Calquence	Acalabrutinib Maleate	12	360	$173,721

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	53	$1,432	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Wei Wang, MD, PHD?

Tedicare shows public-source Medicare data for Wei Wang, MD, PHD (NPI 1861482853), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Wei Wang, MD, PHD have ACO affiliation data?

Wei Wang, MD, PHD is shown with ACO affiliation data for APA ACO Inc. (REACH, ACO ID D0215).

What billing organization is linked to Wei Wang, MD, PHD?

Wei Wang, MD, PHD is linked to SAN FRANCISCO ONCOLOGY ASSOCIATES MEDICAL GROUP INC (billing NPI 1457385379) in the available physician profile data.

Does Wei Wang, MD, PHD have Open Payments data?

Wei Wang, MD, PHD has 53 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.